WGNV Core Group Developed Country NGO Representative
OVERVIEW OF WGNV
The mission of the Working Group on New TB Vaccines (WGNV) is to facilitate research and development of new vaccines to prevent TB by providing an inclusive forum for stakeholders to engage in scientific exchange, build consensus, and advocate for greater support and investment in TB vaccine R&D.
The Working Group on New TB Vaccines (WGNV) was established in 2001. It is one of the nine Working Groups of the Stop TB Partnership. Its purpose is to facilitate the development of new, more effective TB vaccines through collaboration, cooperation, and consensus; and to support the objectives for TB vaccine R&D in the Global Plan to End TB.
The WGNV is an informal network of stakeholders engaged in all aspects of TB vaccine R&D and from all constituencies, including academics, product developers, clinicians, advocates, and affected communities. Membership is open to anyone who is interested in being engaged and involved in TB vaccine R&D.
OVERVIEW OF WGNV CORE GROUP
The WGNV Core Group (CG) is responsible for ensuring the effectiveness of the WGNV through setting strategic direction, accelerating decision making and identifying priority areas of work. CG members are the foundation of the WGNV and must be willing/able to devote time to WGNV activities.
The CG is expected to:
- Oversee and engage in the activities of WGNV
- Monitor progress of WGNV activities
- Assist WGNV Chair/Co-Chairs in addressing strategic and operational issues
- Actively participate in at least one WGNV sub-group or task force
- Meet regularly as required, by telephone or in person
- Collaborate with and consult other Stop TB WGs, Partnership Secretariat and partners on cross-cutting issues
- Serve as an independent, technical, expert advisory group where required by WGNV, the Stop TB Partnership and/or partners
- Ability to work in written and spoken English
- Regular access to internet, email, and phone service
WGNV CG members are expected to contribute a minimum of two (2) hours per month, although actual time per month will vary based on activities. This time is not compensated.
WGNV Core Group Constituency Categories
In order to bring diverse perspectives to the discussions and work of the WGNV, seats on the Core Group are based on constituency groups, with four standing members. Constituency groups include:
- Academic/research institutions
- Industry/private sector
- Clinical trial sites
- Public sector funders
- Philanthropic funders
- Developed country NGOs
- Affected communities
- Early career researchers
- IAVI (standing member)
- TBVI (standing member)
- IVR/WHO (standing member)
- GTBVP (standing member)
Each representative should demonstrate the following:
- Experience working in partnerships
- Ability to be an effective representative of their constituency group WGNV discussions, activities and planning
- Commitment to increasing the visibility of TB vaccine R&D in the overall TB and public health agenda
- Willingness and ability to play a leadership role in developing and advancing the activities strategies of the WGNV that fall within their area(s) of expertise
Developed Country NGO Representative
The Developed Country NGO representative to the WGNV Core Group brings the perspective of Developed Country NGOs to the Core Group and to WGNV strategic planning, priorities, work plans, and activities. The Developed Country NGO representative will lead efforts to make the WGNV an inviting and open platform for this constituency and will present ideas for activities and programs that would increase engagement by this constituency in WGNV and TB vaccine R&D. The term of this position is two years.
In addition to the expectations of all WGNV Core Group members as noted above, the Developed Country NGO representative should meet the following additional criteria:
- Belonging to a community or civil society organization or network based in a developed country
- Actively engaged in TB advocacy
- Demonstrated interest in TB vaccine research and research advocacy
- Willingness and ability to lead WGNV efforts to engage with developed country NGOs to share information and resources, and to expand developed country NGO membership in WGNV and its activities.
Representatives from Developed Country NGOs who are interested in being considered for this position on the WGNV Core Group should submit a CV and letter of interest by 16 December 2022 to email@example.com.
Applications will be reviewed by the WGNV Core Group, and the Core Group will select the Developed Country NGO Representative.
In alignment with the Stop TB Partnership Board Governance Manual, a Developed Country NGO is defined as a national NGO headquartered in any one of the 39 countries defined by the IMF as “advanced economies: Australia, Austria, Belgium, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong SAR, Iceland, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Luxembourg, Macao SAR, Malta, Netherlands, New Zealand, Norway, Portugal, Puerto Rico, San Marino, Singapore, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Taiwan Province of China, United Kingdom, United States